Phase 4 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are an adult (or a minor whose parent/guardian can provide consent) and are willing to sign a consent form to take part in this follow-on study
- You are already taking part in a Novartis-sponsored study receiving crizanlizumab, have completed all the required steps in that original study, and your doctor believes you are benefiting from the treatment
- You have attended your appointments as required in the original study, and your doctor believes you are willing and able to continue attending future appointments
Who may not be able to join:
- You stopped taking crizanlizumab permanently during the original study before that study was finished
- You are currently experiencing serious, unresolved side effects (Grade 3 or higher) related to the treatment, or any side effect that required you to pause your doses — though you may still be considered once milder side effects have cleared up (confirm with trial site)
- You are currently taking part in any other clinical trial (other than the original study), or you plan to join another clinical trial
- You are currently pregnant or breastfeeding
- You are a woman who could become pregnant and are unwilling to use highly effective contraception during treatment and for 15 weeks after stopping crizanlizumab
- You have sickle cell disease but do not meet the original study's requirements to keep receiving crizanlizumab (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Not Applicable as this protocol is to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab study
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.